5-isobutyl-1-phenylpyrazole-3-carboxylic acid | 3191-85-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-isobutyl-1-phenylpyrazole-3-carboxylic acid
• 英文别名: 5-isobutyl-1-phenyl-1H-pyrazole-3-carboxylic acid；5-(2-methylpropyl)-1-phenyl-1H-pyrazole-3-carboxylic acid；5-(2-methylpropyl)-1-phenylpyrazole-3-carboxylic acid
• CAS: 3191-85-3
• 化学式: C₁₄H₁₆N₂O₂
• mdl: MFCD10005848
• 分子量: 244.293
• InChiKey: KXPRFBKERNQEQM-UHFFFAOYSA-N

物化性质

• 熔点：
  129 °C
• 沸点：
  411.7±33.0 °C(Predicted)
• 密度：
  1.16±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-isobutyl-1-phenylpyrazole-3-carboxylic acid 在 盐酸 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 sodium iodide 作用下， 以 乙酸乙酯 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 生成 N-[[4-cyano-1-[[3-(trifluoromethyl)phenyl]methyl]piperidin-4-yl]methyl]-5-(2-methylpropyl)-1-phenylpyrazole-3-carboxamide
  参考文献：
  名称：

  Synthesis and biological evaluation of 4-piperidinecarboxylate and 4-piperidinecyanide derivatives for T-type calcium channel blockers

  摘要：

  To obtain selective and potent inhibitor for T-type calcium channel by ligand based drug design, 4-piperidinecarboxylate and 4-piperidinecyanide derivatives were prepared and evaluated for in vitro and in vivo activity against alpha(1G) calcium channel. Among them, several compounds showed good T-type calcium channel inhibitory activity and minimal off-target activity over hERG channel (% inhibition at 10 mu M = 61.85-71.99, hERG channel IC50 = 1.57 +/- 0.14-4.98 +/- 0.36 mu M). Selected compound 31a was evaluated on SNL model of neuropathic pain and showed inhibitory effect on mechanical allodynia. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.07.087
• 作为产物：
  描述：

  乙基6-甲基-2,4-二氧亚基庚酯 在 水 、 sodium hydroxide 作用下， 以 乙醇 为溶剂， 生成 5-isobutyl-1-phenylpyrazole-3-carboxylic acid
  参考文献：
  名称：

  Synthesis and biological evaluation of 4-piperidinecarboxylate and 4-piperidinecyanide derivatives for T-type calcium channel blockers

  摘要：

  To obtain selective and potent inhibitor for T-type calcium channel by ligand based drug design, 4-piperidinecarboxylate and 4-piperidinecyanide derivatives were prepared and evaluated for in vitro and in vivo activity against alpha(1G) calcium channel. Among them, several compounds showed good T-type calcium channel inhibitory activity and minimal off-target activity over hERG channel (% inhibition at 10 mu M = 61.85-71.99, hERG channel IC50 = 1.57 +/- 0.14-4.98 +/- 0.36 mu M). Selected compound 31a was evaluated on SNL model of neuropathic pain and showed inhibitory effect on mechanical allodynia. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.07.087

文献信息

• Ｔ-형 칼슘 채널에 활성을 가지는 피롤리딘 또는 피페리딘 화합물
  申请人：KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY 한국과학기술연구원(319980077518) BRN ▼209-82-03522

  公开号：KR20200022710A

  公开（公告）日：2020-03-04

  본 발명은 Ｔ-형 칼슘 채널에 활성을 가지는 피롤리딘 또는 피페리딘 화합물에 대한 것으로, 더욱 자세하게는 본 발명에 따른 화학식 1로 표시되는 피롤리딘 또는 피페리딘 화합물은, T-형 칼슘채널에 대하여 우수한 길항작용을 가지고 있어서, 간질, 고혈압 등의 뇌질환, 협심증 등의 심장질환, 만성 통증, 신경성 통증 등의 통증질환, 또는 암과 관련 질병의 예방 또는 치료제로서 유용하게 사용될 수 있다.

  本发明涉及对T型钙通道具有活性的吡啶或哌啶化合物，更具体地说，根据本发明，化学式1所示的吡啶或哌啶化合物对T型钙通道具有优异的抑制作用，可用于治疗或预防癫痫、高血压等脑部疾病，心脏疾病如心绞痛，慢性疼痛，神经性疼痛等疼痛性疾病，以及与癌症相关的疾病。
• Synthesis and evaluation of 6-pyrazoylamido-3 N -substituted azabicyclo[3,1,0]hexane derivatives as T-type calcium channel inhibitors for treatment of neuropathic pain
  作者：Jung Hyun Kim、Ghilsoo Nam

  DOI：10.1016/j.bmc.2016.06.006

  日期：2016.11

  to 3N-substituted-azabicyclo[3.1.0]hexane derivatives were designed and synthesized as inhibitors of T-type calcium channels. Among the synthesized compounds, 3N-R-substituted azabicyclo[3.1.0]hexane carboxamide derivatives containing 5-isobutyl-1-phenyl-pyrazole ring exhibited potent and selective T-channel inhibition and good metabolic stability without CYP450 inhibition. Compounds 10d and 10e contained

  设计并合成了一系列新的芳基化合物，包括与3 N-取代的氮杂双环[3.1.0]己烷衍生物共轭的苯并[ d ]咪唑/异恶唑/吡唑，并作为T型钙通道抑制剂。在合成的化合物中，含有5-异丁基-1-苯基-吡唑环的3 N - R-取代的氮杂双环[3.1.0]己烷甲酰胺衍生物表现出有效的和选择性的T通道抑制作用，并且具有良好的代谢稳定性，而没有CYP450抑制作用。化合物10D和10E含有疏水取代基在3- Ñ位和表现出在体外效力强效，以及在大鼠神经性疼痛减轻。
• Synthesis and biological evaluation of pyrrolidine-based T-type calcium channel inhibitors for the treatment of neuropathic pain
  作者：Hak Kyun Yang、Woo Seung Son、Keon Seung Lim、Gun Hee Kim、Eun Jeong Lim、Changdev G. Gadhe、Jae Yeol Lee、Kyu-Sung Jeong、Sang Min Lim、Ae Nim Pae

  DOI：10.1080/14756366.2018.1513926

  日期：2018.1.1

  T-type channel inhibitors showed promising in vivo efficacy in neuropathic pain animal models and are being investigated in clinical trials. Herein we report development of novel pyrrolidine-based T-type calcium channel inhibitors by pharmacophore mapping and structural hybridisation followed by evaluation of their Cav3.1 and Cav3.2 channel inhibitory activities. Among potent inhibitors against both

  神经性疼痛的治疗是迫切的医疗需求之一，T型钙通道是神经性疼痛的有希望的治疗靶点。几种有效的T型通道抑制剂在神经性疼痛动物模型中显示出有希望的体内功效，并且正在临床试验中进行研究。在本文中，我们报告了通过药效基团定位和结构杂交，然后对其Cav3.1和Cav3.2通道抑制活性进行评估的新型基于吡咯烷的T型钙通道抑制剂的开发。根据体内药代动力学研究，在针对Cav3.1和Cav3.2通道的有效抑制剂中，一种基于体外ADME特性的有前途的化合物20n在大鼠中显示出令人满意的血浆和脑暴露。
• US2014/343295
  申请人：——

  公开号：——

  公开（公告）日：——
• US20140343295A1
  申请人：——

  公开号：US20140343295A1

  公开（公告）日：2014-11-20